Wilcox 2011.

Methods	Double‐blind placebo‐controlled trial Pilot study Setting: (not specified), USA Recruitment: community volunteers Study period: not reported
Participants	N = 78 Inclusion criteria: male and female white smokers of European descent, at least 18 years of age, who were smoking ≥ 10 cigarettes/d for ≥ 5 years and were in generally good physical and mental health Exclusion criteria: not reported
Interventions	Rimonabant 20 mg/d (n = 48) vs placebo (n = 28) for 10 weeks
Outcomes	Smoking status; exhaled CO level
Funding source	This study reports analysis of pharmacogenetics.
Declaration of interest	Pharmacology Research Institute and laboratory of one of the study authors at the University of California Los Angeles (UCLA)
Notes	Not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No relevant information reported
Allocation concealment (selection bias)	Unclear risk	No relevant information reported
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double‐blind design but no other information reported
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Double‐blind design but no other information reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not reported
Selective reporting (reporting bias)	Unclear risk	No information on protocol availability reported
Other bias	Unclear risk	Distribution of ethnicities between treatment groups unclear